Key Insights

Highlights

Success Rate

78% trial completion

Published Results

57 trials with published results (11%)

Research Maturity

170 completed trials (33% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.1%

47 terminated out of 516 trials

Success Rate

78.3%

-8.2% vs benchmark

Late-Stage Pipeline

3%

16 trials in Phase 3/4

Results Transparency

34%

57 of 170 completed with results

Key Signals

57 with results78% success47 terminated

Data Visualizations

Phase Distribution

377Total
Not Applicable (125)
Early P 1 (28)
P 1 (118)
P 2 (90)
P 3 (13)
P 4 (3)

Trial Status

Completed170
Recruiting126
Unknown88
Terminated47
Not Yet Recruiting30
Active Not Recruiting25

Trial Success Rate

78.3%

Benchmark: 86.5%

Based on 170 completed trials

Clinical Trials (516)

Showing 20 of 20 trials
NCT06804655Phase 2Not Yet Recruiting

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

NCT07416188Phase 1Not Yet Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT04699773Not ApplicableRecruitingPrimary

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

NCT05538130Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT04274283RecruitingPrimary

Tessa Jowell BRAIN MATRIX - Platform Study

NCT07076498Phase 1RecruitingPrimary

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT05355701Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT06101069Not ApplicableRecruiting

Development of MRF for Characterization of Brain Tumors After Radiotherapy

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT07464925Phase 1Recruiting

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT05555550Early Phase 1RecruitingPrimary

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

NCT06625047Phase 4Completed

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

NCT07210632Early Phase 1Recruiting

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT07539441Phase 1Recruiting

A Study of Mirdametinib in People With Central Nervous System Tumors

NCT04065776Not ApplicableRecruitingPrimary

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

NCT02022800Not ApplicableCompletedPrimary

Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)

NCT07547163RecruitingPrimary

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

NCT04687969Active Not Recruiting

Multimodal Machine Learning Characterization of Solid Tumors

NCT07243470Phase 1RecruitingPrimary

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Scroll to load more

Research Network

Activity Timeline